100s of titles, one news app for just $10 a month.
Dive Deeper:
Arcellx Doses First Patient in Phase 1 study of ACLX-001 in Relapsed or Refractory Multiple Myeloma
Arcellx, Inc. (NASDAQ: ACLX) announced that the first patient has been dosed in its open-label, multi centre phase 1 clinical…
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours:
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis
Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and…
One subscription that gives you access to news from hundreds of sites
COCP: Cocrystal Pharma Releases 2022 1st Quarter Results and Provides an Update on the Current Pipeline Programs
By Thomas Kerr, CFA NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours:
Get all your news in one place
Latest Technology news:
Musk and Bezos Agree on Who Is Responsible for Inflation
The two richest men in the world appear to have teamed up against a common adversary.
Read news from The Economist, FT, Bloomberg and more, with one subscription
Learn More
Cadillac Lyriq To Come With 2 Years Of Free Charging On EVgo Network
We examine the announcement that the 2023 Cadillac Lyriq will come with two years of unlimited free charging on the…
Tesla Model 3 RWD 5-Year Cost Of Ownership Versus Toyota Camry
The Tesla's 2021 Impact Report highlights a very interesting presentation of the total cost of ownership of the entry-level 2021…
Boeing’s Starliner spacecraft takes another shot at the International Space Station
In this edition of Horizons, learn about Boeing's Starliner capsule test, mRNA vaccine technology updates, and more from the world…
New PS Plus games list exposes a major flaw in Sony's Game Pass rival
Sony has shared a list of some of the game available on its new PS Plus service, but there's a…
From analysis to good news, read the world’s best news in one place
Urban Drivestyle And SNIPES Collab To Release Two Limited-Edition E-Bikes
Boutique e-bike manufacturer Urban Drivestyle has joined forces with SNIPES for a unique lineup of electric bicycles.
ABB And Shell Announce Nationwide Deployment Of 360 kW Chargers In Germany
Germany soon will get a major boost to its DC fast charging infrastructure to support the electrification of the market.

Caribou's Lymphoma Candidate Shows 100% Response Rate In Early-Stage Study

By Vandana Singh
  • Caribou Biosciences Inc (NASDAQ:CRBU) announced initial data from its ANTLER Phase 1 trial for CB-010 in relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL).
  • These initial data will be shared at the European Hematology Association (EHA) 2022 Hybrid Congress.
  • The EHA abstract includes safety, tolerability, and initial antitumor activity of CB-010 administered at dose level 1 (40x106 CAR-T cells) to 6 patients with r/r B-NHL who had relapsed after previous treatment.
  • As of the February 23 data cutoff date, six patients had been treated with CB-010, and five had completed the 28-day dose-limiting toxicity (DLT) evaluation period.
  • 100% (n=5) achieved an overall response rate (ORR), including 80% (n=4) achieved a complete response rate (CR), and 20% (n=1) achieved a partial response (PR). 
  • All four patients who achieved a CR at 28 days had an ongoing CR at 3 months. The longest measured CR as of the data cutoff date was 6 months.
  • Following treatment with CB-010, there was no graft versus host disease cases. 3 of 6 patients developed severe adverse events within the first 28 days: neutropenia (50%), thrombocytopenia (33%), anemia (17%), and hypogammaglobulinemia (17%). 
  • The company is now enrolling patients in cohort 2 of the ANTLER trial at dose level 2 (80x106 CAR-T cells). Additional data are expected by year-end.
  • Price Action: CRBU shares are up 22.20% at $8.10 during the market session on the last check Thursday.
What is inkl?
The world’s most important news, from 100+ trusted global sources, in one place.
Morning Edition
Your daily
news overview

Morning Edition ensures you start your day well informed.

No paywalls, no clickbait, no ads
Enjoy beautiful reading

Content is only half the story. The world's best news experience is free from distraction: ad-free, clickbait-free, and beautifully designed.

Expert Curation
The news you need to know

Stories are ranked by proprietary algorithms based on importance and curated by real news journalists to ensure that you receive the most important stories as they break.

Dive Deeper:
Arcellx Doses First Patient in Phase 1 study of ACLX-001 in Relapsed or Refractory Multiple Myeloma
Arcellx, Inc. (NASDAQ: ACLX) announced that the first patient has been dosed in its open-label, multi centre phase 1 clinical…
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours:
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis
Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and…
One subscription that gives you access to news from hundreds of sites
COCP: Cocrystal Pharma Releases 2022 1st Quarter Results and Provides an Update on the Current Pipeline Programs
By Thomas Kerr, CFA NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours:
Get all your news in one place